CN111377871B - 一种fak抑制剂及其联合用药物 - Google Patents
一种fak抑制剂及其联合用药物 Download PDFInfo
- Publication number
- CN111377871B CN111377871B CN201911350837.8A CN201911350837A CN111377871B CN 111377871 B CN111377871 B CN 111377871B CN 201911350837 A CN201911350837 A CN 201911350837A CN 111377871 B CN111377871 B CN 111377871B
- Authority
- CN
- China
- Prior art keywords
- compound
- deuterated
- cancer
- fak
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 229940124783 FAK inhibitor Drugs 0.000 title abstract description 21
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 59
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims description 12
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 claims description 11
- 101000611935 Mus musculus Programmed cell death protein 1 Proteins 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 229940041181 antineoplastic drug Drugs 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 98
- 230000000694 effects Effects 0.000 abstract description 18
- 239000012270 PD-1 inhibitor Substances 0.000 abstract description 12
- 239000012668 PD-1-inhibitor Substances 0.000 abstract description 12
- 229940121655 pd-1 inhibitor Drugs 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 150000003839 salts Chemical class 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 230000003287 optical effect Effects 0.000 abstract description 4
- 229940002612 prodrug Drugs 0.000 abstract description 4
- 239000000651 prodrug Substances 0.000 abstract description 4
- 239000012453 solvate Substances 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 3
- 230000002503 metabolic effect Effects 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- 229910052739 hydrogen Inorganic materials 0.000 description 54
- 239000001257 hydrogen Substances 0.000 description 54
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 43
- -1 alkoxyamide Chemical compound 0.000 description 29
- 229940079593 drug Drugs 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 27
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 27
- 238000003756 stirring Methods 0.000 description 27
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 19
- 229910052805 deuterium Inorganic materials 0.000 description 18
- 238000002390 rotary evaporation Methods 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 14
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical class CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 239000012043 crude product Substances 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 10
- 201000001441 melanoma Diseases 0.000 description 10
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 10
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000005457 ice water Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 208000009956 adenocarcinoma Diseases 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 6
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 229950008937 defactinib Drugs 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000002386 leaching Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- FWLMVFUGMHIOAA-UHFFFAOYSA-N n-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(NCC=2C(=NC=CN=2)N(C)S(C)(=O)=O)=N1 FWLMVFUGMHIOAA-UHFFFAOYSA-N 0.000 description 5
- 150000004885 piperazines Chemical class 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000005760 tumorsuppression Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 4
- WJXISSUHFHNULL-UHFFFAOYSA-N 4-[[4-chloro-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1NC1=NC=C(C(F)(F)F)C(Cl)=N1 WJXISSUHFHNULL-UHFFFAOYSA-N 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010027406 Mesothelioma Diseases 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 4
- 229940125846 compound 25 Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical class [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- IDRUEHMBFUJKAK-UHFFFAOYSA-N 2,4-dichloro-5-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CN=C(Cl)N=C1Cl IDRUEHMBFUJKAK-UHFFFAOYSA-N 0.000 description 3
- IJEBTSOYCUVHFB-UHFFFAOYSA-N 4-[[4-chloro-5-(trifluoromethyl)pyrimidin-2-yl]amino]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(Cl)=N1 IJEBTSOYCUVHFB-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229940126540 compound 41 Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940102001 zinc bromide Drugs 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical class CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 description 2
- RJARWVQMFGDOSU-UHFFFAOYSA-N 2-methylbenzamide;2,2,2-trifluoroacetic acid Chemical class OC(=O)C(F)(F)F.CC1=CC=CC=C1C(N)=O RJARWVQMFGDOSU-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- ZJDBQMWMDZEONW-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonylamino]benzoic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=C(C(O)=O)C=C1 ZJDBQMWMDZEONW-UHFFFAOYSA-N 0.000 description 2
- IJEBTSOYCUVHFB-FIBGUPNXSA-N 4-[[4-chloro-5-(trifluoromethyl)pyrimidin-2-yl]amino]-N-(trideuteriomethyl)benzamide Chemical compound [2H]C([2H])([2H])NC(=O)C1=CC=C(NC2=NC(Cl)=C(C=N2)C(F)(F)F)C=C1 IJEBTSOYCUVHFB-FIBGUPNXSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- RPFZUVBFWZFXSD-UHFFFAOYSA-N FC(C(=O)O)(F)F.NC1=CC=C(C(=O)NC)C=C1 Chemical compound FC(C(=O)O)(F)F.NC1=CC=C(C(=O)NC)C=C1 RPFZUVBFWZFXSD-UHFFFAOYSA-N 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- BGVJHAYXHSRENE-FIBGUPNXSA-N N-(3-cyanopyrazin-2-yl)-N-(trideuteriomethyl)methanesulfonamide Chemical compound [2H]C([2H])([2H])N(C1=NC=CN=C1C#N)S(C)(=O)=O BGVJHAYXHSRENE-FIBGUPNXSA-N 0.000 description 2
- UHNHTTIUNATJKL-FIBGUPNXSA-N N-(trideuteriomethyl)methanesulfonamide Chemical compound [2H]C(NS(=O)(=O)C)([2H])[2H] UHNHTTIUNATJKL-FIBGUPNXSA-N 0.000 description 2
- IETKYMZYQKEXLW-FIBGUPNXSA-N N-[3-(aminomethyl)pyrazin-2-yl]-N-(trideuteriomethyl)methanesulfonamide Chemical compound [2H]C([2H])([2H])N(C1=NC=CN=C1CN)S(C)(=O)=O IETKYMZYQKEXLW-FIBGUPNXSA-N 0.000 description 2
- 201000004404 Neurofibroma Diseases 0.000 description 2
- 208000005890 Neuroma Diseases 0.000 description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 2
- 208000037844 advanced solid tumor Diseases 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 208000030381 cutaneous melanoma Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000006178 malignant mesothelioma Diseases 0.000 description 2
- 201000005282 malignant pleural mesothelioma Diseases 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 208000037843 metastatic solid tumor Diseases 0.000 description 2
- DGEIIMKQJPHIDZ-UHFFFAOYSA-N n-methoxyethanamine Chemical compound CCNOC DGEIIMKQJPHIDZ-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 206010061311 nervous system neoplasm Diseases 0.000 description 2
- 208000007538 neurilemmoma Diseases 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 201000003437 pleural cancer Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 2
- 206010039667 schwannoma Diseases 0.000 description 2
- 201000003708 skin melanoma Diseases 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- YKLVHERADAJQQV-NGQKKBAQSA-N (8R,9S,13S,14S,17R)-4-fluoro-17-hydroxy-13-methyl-17-[(1-oxidopyridin-1-ium-4-yl)methyl]-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3-carbonitrile Chemical compound C([C@]1(O)CC[C@H]2[C@H]3[C@@H](C4=CC=C(C(F)=C4CC3)C#N)CC[C@@]21C)C1=CC=[N+]([O-])C=C1 YKLVHERADAJQQV-NGQKKBAQSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- UYJNQQDJUOUFQJ-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-morpholinyl)anilino]-4-pyrimidinyl]amino]-N-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1Cl UYJNQQDJUOUFQJ-UHFFFAOYSA-N 0.000 description 1
- KOTIFMIIUXOURZ-UHFFFAOYSA-N 2-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical class CS(=O)(=O)N(C)C1=NC=CN=C1CNC1=NC(NC=2C=C(C)C(C(N)=O)=CC=2)=NC=C1C(F)(F)F KOTIFMIIUXOURZ-UHFFFAOYSA-N 0.000 description 1
- SDLFAEGTVBPHBK-UHFFFAOYSA-N 3-chloropyrazine-2-carbonitrile Chemical compound ClC1=NC=CN=C1C#N SDLFAEGTVBPHBK-UHFFFAOYSA-N 0.000 description 1
- QIKYZXDTTPVVAC-UHFFFAOYSA-N 4-Aminobenzamide Chemical compound NC(=O)C1=CC=C(N)C=C1 QIKYZXDTTPVVAC-UHFFFAOYSA-N 0.000 description 1
- QKKPJFTYJCXESR-OAQYLSRUSA-N 4-[(5r)-3-[4-cyano-3-(trifluoromethyl)phenyl]-4-oxo-2-sulfanylidene-7-oxa-1,3-diazaspiro[4.4]nonan-1-yl]-2-fluoro-n-methylbenzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1[C@]2(COCC2)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S QKKPJFTYJCXESR-OAQYLSRUSA-N 0.000 description 1
- KRBMOYIWQCZVHA-INIZCTEOSA-N 4-[3-[4-[(2s)-2,3-dihydroxypropoxy]phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound O=C1C(C)(C)N(C=2C=CC(OC[C@@H](O)CO)=CC=2)C(=S)N1C1=CC=C(C#N)C(C(F)(F)F)=C1 KRBMOYIWQCZVHA-INIZCTEOSA-N 0.000 description 1
- WXCXUHSOUPDCQV-HPRDVNIFSA-N 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-n-(trideuteriomethyl)benzamide Chemical compound C1=C(F)C(C(=O)NC([2H])([2H])[2H])=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-HPRDVNIFSA-N 0.000 description 1
- ALYNCZNDIQEVRV-QDNHWIQGSA-N 4-amino-2,6-dideuteriobenzoic acid Chemical compound [2H]C1=CC(N)=CC([2H])=C1C(O)=O ALYNCZNDIQEVRV-QDNHWIQGSA-N 0.000 description 1
- ALYNCZNDIQEVRV-NMQOAUCRSA-N 4-amino-3,5-dideuteriobenzoic acid Chemical compound [2H]C1=CC(C(O)=O)=CC([2H])=C1N ALYNCZNDIQEVRV-NMQOAUCRSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229940127512 Androgen Synthesis Inhibitors Drugs 0.000 description 1
- 108091005625 BRD4 Proteins 0.000 description 1
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- FWLMVFUGMHIOAA-BMSJAHLVSA-N N-methyl-4-[[4-[[3-[methylsulfonyl(trideuteriomethyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical compound [2H]C([2H])([2H])N(C1=NC=CN=C1CNC1=C(C=NC(NC2=CC=C(C=C2)C(=O)NC)=N1)C(F)(F)F)S(C)(=O)=O FWLMVFUGMHIOAA-BMSJAHLVSA-N 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 description 1
- 229950007511 apalutamide Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- SNIABFMMCKVXSY-UHFFFAOYSA-N benzoylazanium;chloride Chemical compound Cl.NC(=O)C1=CC=CC=C1 SNIABFMMCKVXSY-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- HDTYUHNZRYZEEB-UHFFFAOYSA-N bisphenol A (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) ether Chemical compound C=1C=C(OCC(O)CCl)C=CC=1C(C)(C)C1=CC=C(OCC(O)CO)C=C1 HDTYUHNZRYZEEB-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- BLIJXOOIHRSQRB-PXYINDEMSA-N n-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide Chemical compound C([C@H](C)NC(=O)C=1NN=C(C=1)C(C)O)N(N=1)C=CC=1C1=CC=C(C#N)C(Cl)=C1 BLIJXOOIHRSQRB-PXYINDEMSA-N 0.000 description 1
- 229940127284 new molecular entity Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940073452 rezvilutamide Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940121497 sintilimab Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
技术领域
本发明属于药物化学领域,具体涉及一种FAK抑制剂及其联合用药物。
背景技术
黏着斑激酶(focal adhesion kinase,FAK)是一种细胞内的非受体酪氨酸激酶,在转染的V-Src鸡胚成纤维细胞中被首次发现。FAK在多数组织中都有较高的表达,其蛋白序列在很多物种(鼠、蟾蜍、人等)中具有较高的同源性。FAK在细胞内是多条信号传导通路的交汇处,参与肿瘤形成、增殖、转移和凋亡、心血管疾病等多个生物过程,是目前受到广泛关注的抗肿瘤靶点之一。
近年来的研究发现,FAK可经多种因素激活,包括整合素、G蛋白偶联受体等,同时FAK经激酶依赖和非激酶依赖2种途径调控细胞内P53、PI3K-AKT-mTOR等信号通路,参与肿瘤细胞的生存、增殖、转移等生物过程。最初的尝试是通过下调FAK在肿瘤细胞中的表达以达到抑制肿瘤的目的。通过转染羧基端失活的FAK(FAK-CD)沉默FAK,减少细胞黏着和增殖,在活体实验中实现了抑制乳腺癌细胞生长的作用。通过转染含有FAK-silenced RNA(FAK-siRNA)的质粒,在活体内抑制了癌症。同时抑制FAK和FAK下游信号分子(如SRC)的表达,能够使得抗肿瘤效应增强。
考虑到FAK在肿瘤细胞中的重要功能、基因转染的可靠性和病毒载体的安全性,基于FAK信号通路的小分子抑制剂开始出现,并且近年来取得较好的成果。目前有多种FAK抑制剂作为抗肿瘤药物,处于临床前研究或临床试验阶段。有文献报道(抗肿瘤新靶点黏着斑激酶FAK及其抑制剂研究进展,陈瑛等),TAE226又称NVP-226可以通过阻滞FAK与ATP的连接位点以及FAK的Y397和Y861磷酸化位点,起到抑制FAK活性的作用。然而,本领域仍需要开发具有更佳的抑制活性或更好药效学性能的FAK抑制剂。
氘代药物是指将药物分子中的部分氢原子替换为氘,氘(D)是氢的一种稳定同位素,由于氘在药物中的形态和体积与氢基本相同,将药物分子中部分氢原子替代为氘,药物分子活性基本保持不变。此外,由于氘原子质量是氢的两倍,碳氘键(C-D)比碳氢键(C-H)的振动零点能要低,碳氘键更稳定,将药物分子中部分氢原子替代为氘,会延缓药物的分解过程,使氘代药物在体内作用时间更长,达到改变药物代谢速度或代谢途径的目的,以此提高药代动力学、降低药物代谢毒性。鉴于FAK抑制剂在肿瘤治疗领域的重要用途和其局限性,将其与氘代药物技术结合,发现新的分子实体,降低其对肝肾功能的影响、提升药物安全性和有效性是促进这一种类药物进一步发展的研究趋势,具有巨大的应用价值。
药物联合使用是有效提高药物疗效的方式,未见将氘代FAK抑制剂与其他的抗癌药物或者抗癌方法联合使用的报道。
发明内容:
为了解决上述问题,本发明提供了一种氘代化合物及其作为FAK抑制剂的用途,还提供了前述氘代化合物与其他抗癌药物联合使用的方案。
本发明提供了式(I)所示的化合物或其光学异构体、互变异构体、药学上可接受的盐、前药、水合物或溶剂合物:
其中,S环选自芳环或五元杂环;A、B,X、Y,Z分别独立地选自碳或氮;E为无或亚甲基;
和/或,R6选自氢或无;R7选自氢,氮或无;R8选自卤代烷基或卤素,或者,R7和R8连接成环;
和/或,R9选自-NMeSO2Me、-CONHOMe、-CONHMe、酰胺、氢或无;R10选自氢或无;R11选自-NHSO2Me、卤素、取代的哌嗪或氢,所述哌嗪上的取代基为乙醇基;R12选自-SO2Me或氢;R13选自-CONHMe、-CONHOMe、N-烷基磺酰胺、氢或无,或者,R11和R13连接成环;
式(I)所示Dx表示括号内的化合物至少1个碳原子上的氢被氘取代,x为大于或等于1的整数。
优选地,所述化合物具有式(I-A)所示结构:
其中,A、B,X,Y,Z分别独立地选自碳或氮;E为无或亚甲基;
R1、R5选自氢或甲氧基;R2、R4选自氢或甲氧基,R3选自氢、-CONHMe、烷氧基酰胺、吗啉、甲氧基、乙基胺或磺酰胺,或者,R2和R3连接成环,或者,R3和R4连接成环;
和/或,R6选自氢或无;R7选自氢,氮或无,R8选自卤代烷基或卤素,或者,R7和R8连接成环;
和/或,R9选自-NMeSO2Me、-CONHOMe、-CONHMe、酰胺、氢或无;R10选自氢或无;R11选自-NHSO2Me、卤素、取代的哌嗪或氢,所述哌嗪上的取代基为乙醇基;R12选自-SO2Me或氢;R13选自-CONHMe、N-烷基磺酰胺、氢或无,或者,R11和R13连接成环,或者,R13和R3和R4连接成环;
式(I-A)所示Dx表示括号内的化合物至少1个碳原子上的氢被氘取代,x为大于或等于1的整数。
优选地,所述化合物具有式(I-B)所示结构:
其中,A、X、Y选自碳或氮;E为无;
R14,R15,R16独立地选自氢,C1-6烷基,C3-6环烷基,甲基、乙基或异丙基;
和/或,R6为氢;R7为氢;R8为卤素;
R9、R13选自-CONHOMe、-CONHMe或氢;R10、R12为氢;
R11选自卤素、氢或取代的哌嗪,所述哌嗪上的取代基为乙醇基;
式(I-B)所示Dx表示括号内的化合物至少1个碳原子上的氢被氘取代,x为大于或等于1的整数。
优选地,所述化合物具有式(I-C)所示结构:
其中,A、X、Y选自碳或氮;E选自亚甲基或无;
R9、R13选自氢、-NMeSO2Me、-CONHOMe或-CONHMe;R10、R12为氢;R11选自氢、取代的哌嗪或卤素,所述哌嗪上的取代基为乙醇基;
和/或,R6选自氢;R7选自氢,R8选自卤代烷基或卤素,或者,R7和R8连接成环;
和/或,R1、R4、R5选自氢或甲氧基;R2选自氢或甲氧基,R3选自氢、-CONHMe、烷氧基酰胺、吗啉、甲氧基、乙基胺或磺酰胺,或者,R2和R3连接成环;
式(I-C)所示Dx表示括号内的化合物至少1个碳原子上的氢被氘取代,x为大于或等于1的整数。
优选地,所述化合物具有式(I-D)所示结构:
其中,R9、R13选自-CONHOMe、-CONHMe或氢;R10、R12为氢;R11选自卤素、氢或取代的哌嗪,所述哌嗪上的取代基为乙醇基;
A、X、Y选自碳或氮;E为无;
和/或,R6选自氢;R7选自氢;R8为卤素
和/或,R14选自甲基、乙基或异丙基;R15选自甲基或氢;R16为氢;
式(I-D)所示Dx表示括号内的化合物至少1个碳原子上的氢被氘取代,x为大于或等于1的整数。
优选地,所述化合物具有式(I-E)所示结构:
其中,B、Z选自碳或氮;E为亚甲基;Y为氮;X、A为碳;
和/或,R6为无;R7为氢;R8为卤代烷基;
和/或,R1、R2为氢;R3为-CONHMe,R4为氢,或者,R3与R4连接成环;
式(I-E)所示Dx表示括号内的化合物至少1个碳原子上的氢被氘取代,x为大于或等于1的整数。
优选地,所述化合物具有式(I-F)所示结构:
其中,式(I-F)所示Dx表示括号内的化合物至少1个碳原子上的氢被氘取代,x为大于或等于1的整数。
优选地,所述化合物具有式(I-G)所示结构:
其中,R1、R5、R17、R18、R19、R20、R21、R22、R23、R24中的一个或多个被氘取代。
优选地,所述化合物选自但不局限于氘取代的如下化合物之一:
优选地,所述化合物选自但不局限于如下化合物之一或氘取代的如下化合物之一:
本发明还提供了前述化合物或其光学异构体、互变异构体、药学上可接受的盐、前药、水合物或溶剂合物在制备FAK抑制剂中的用途;优选地,所述FAK抑制剂是治疗癌症的药物。
其中,所述癌症为实体瘤;
所述实体瘤包括间皮瘤,胰腺癌,软组织肿瘤,转移瘤,非固体癌,肉瘤,腺癌,肺癌,乳腺癌,淋巴瘤,胃肠道癌,泌尿生殖系统癌,前列腺癌,卵巢癌;所述胃肠道癌包括结肠癌,所述泌尿生殖系统癌包括肾,尿路上皮或睾丸肿瘤,所述卵巢癌包括晚期卵巢癌;
所述间皮瘤包括神经纤维瘤,肾癌,肺癌,小细胞肺癌,非小细胞肺癌,KRAS突变体非小细胞肺癌,肝癌,甲状腺癌,乳腺癌,神经系统肿瘤,神经鞘瘤,脑膜瘤,神经瘤,腺样囊性癌,室管膜瘤,室管膜肿瘤,恶性胸膜瘤,恶性胸膜间皮瘤,三联体瘤,阴性乳腺癌,非血液恶性肿瘤,黑素瘤,,结直肠癌,白血病,腺癌,固体肿瘤;
所述黑素瘤包括局部晚期黑素瘤,局部突变的N-Ras引起的黑素瘤,转移性恶性皮肤黑色素瘤,所述结直肠癌包括转移性结直肠癌,所述白血病包括急性髓性白血病,所述腺癌包括腺癌,所述固体肿瘤包括局部晚期实体瘤,转移性实体瘤,肝细胞癌。
本发明还提供了一种用于治疗肿瘤的联合用药物,它含有相同或不同规格单位制剂的用于同时或者分别给药的前述化合物与抗癌药物,以及药学上可接受的载体。
所述抗癌药物为免疫疗法用药物、化学疗法用药物或辐射疗法用药物。
所述免疫疗法用药物选自检查点抑制剂、PD-1抑制剂、PD-L1抑制剂、抑制CTLA-4的抗体、抑制TIM3的抗体、抑制LAG3的抗体、抑制TIGIT的抗体、阻断检查点靶点的抗体、共刺激抗体或者CAR-T疗法用细胞。
所述PD-1抑制剂或PD-L1抑制剂,包括但不局限于:nivolumab,CT-011;AMP-224,pembrolizumab,pidilizumab,MK-3475,BMS936559,MEDI4736,MSB001071 8C,MPDL-3280A,SHR-1210,IBI308,BGB-A317,JS001,GLS-010,GB226杰诺单抗,HLX10,AK103,AK104,AK105,AK112,SSI-361,JY034,KN035,SHR1316,TQB2450,KL-A167,CS1001,STI-A1014,JS003,AK106,HLX-09,mPD-1抗体;
所述阻断检查点靶点的抗体包括IMP321,MGA271;
所述共刺激抗体包括anti-4-lBB抗体,anti-OX40抗体,anti-GITR抗体,anti-CD27抗体,anti-CD40抗体。
所述化学疗法用药物为毒性药物,烷基化药物,抗代谢产物药物,抗生素,激素疗法药物,天然产物抗癌药物,拓扑异构酶抑制剂药物,免疫药物,络合铂药物,激酶抑制剂,抗增生药物,抗体,干扰素或调控雄激素信号通路的药物。
所述毒性药物为包括但不局限于gemcitabine,paclitaxel,docetaxel;
所述激酶抑制剂包括但不局限于,MEK激酶抑制剂,cMet抑制剂,VEGFR2抑制剂,EGFR抑制剂;
所述调控雄激素信号通路的药物包括但不局限于:雄激素合成抑制剂,CYP17A抑制剂,雄激素受体抑制剂,BET抑制剂,BRD4抑制剂,RORγ抑制剂,CBP/P300抑制剂,BMX抑制剂,PARP抑制剂;优选地,所述雄激素受体抑制剂包括但不局限于:Enzalutamide,Apalutamide,Bicalutamide,Abiraterone,ODM-201,EPI-001,ONC1-13B,EM-5854,JNJ-63576,TAS-3681,HC-1119,普克鲁胺,SHR3680。
本发明还提供了前述联合用药物在制备治疗癌症的药物中的用途。
其中,所述癌症为实体瘤;
所述实体瘤包括间皮瘤,胰腺癌,软组织肿瘤,转移瘤,非固体癌,肉瘤,腺癌,肺癌,乳腺癌,淋巴瘤,胃肠道癌,泌尿生殖系统癌,前列腺癌,卵巢癌;所述胃肠道癌包括结肠癌,所述泌尿生殖系统癌包括肾,尿路上皮或睾丸肿瘤,所述卵巢癌包括晚期卵巢癌;
所述间皮瘤包括神经纤维瘤,肾癌,肺癌,小细胞肺癌,非小细胞肺癌,KRAS突变体非小细胞肺癌,肝癌,甲状腺癌,乳腺癌,神经系统肿瘤,神经鞘瘤,脑膜瘤,神经瘤,腺样囊性癌,室管膜瘤,室管膜肿瘤,恶性胸膜瘤,恶性胸膜间皮瘤,三联体瘤,阴性乳腺癌,非血液恶性肿瘤,黑素瘤,,结直肠癌,白血病,腺癌,固体肿瘤;
所述黑素瘤包括局部晚期黑素瘤,局部突变的N-Ras引起的黑素瘤,转移性恶性皮肤黑色素瘤,所述结直肠癌包括转移性结直肠癌,所述白血病包括急性髓性白血病,所述腺癌包括腺癌,所述固体肿瘤包括局部晚期实体瘤,转移性实体瘤,肝细胞癌。
本发明中,“烷基”包括直链或支链的烷基。
本发明中,术语“本发明化合物”指式(Ⅰ)所示的化合物。该术语还包括式(Ⅰ)化合物的各种晶型形式、药学上可接受的盐、水合物或溶剂合物、光学异构体、互变异构体、前药。
本发明中,术语“药学上可接受的盐”指本发明化合物与酸或碱所形成的适合用作药物的盐。药学上可接受的盐包括无机盐和有机盐。一类优选的盐是本发明化合物与碱金属形成的盐。适合形成盐的碱金属包括但并不限于:锂、钠,钾、钙、镁等。
本发明化合物或药物组合物的施用方式没有特别限制,代表性的施用方式包括(但并不限于):口服、肠胃外(静脉内、肌肉内或皮下)、和局部给药。
本发明提供了一种氘代化合物,与氘代前的化合物相比,其显示了更优的药代动力学,更高的最高血药浓度,更高的暴露量和更长的半衰期,具有更加优异的代谢性能。而且,本发明的氘代化合物能够有效抑制FAK活性,在制备FAK抑制剂和/或治疗癌症的药物中具有非常好的应用前景。同时,本发明的氘代化合物与抗癌药物(比如PD-1抑制剂)联合使用能够发挥协同增效的作用,显著提高肿瘤抑制效果,为临床治疗癌症提供了更好的选择。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1为本发明氘代化合物在MC38肿瘤动物模型上的药效实验。
图2为本发明氘代化合物在PAN02肿瘤动物模型上的药效实验。
具体实施方式
本发明所用原料和仪器均可通过市场购买得到。
实施例1、合成N-三氘代甲基-4-((4-(((3-(N-甲基甲磺酰胺基)吡嗪-2-基)甲基)氨基)-5-(三氟甲基)嘧啶-2-基)氨基)苯甲酸酰胺(化合物25)
第一步:合成化合物25-2
将25-1(200mg,0.39mmol),DMAP(1.29g,10.57mmol)加入到10mL二氯甲烷中,再滴加(Boc)2O(1.71g,7.83mmol)。体系在油浴中回流反应24h。翌日,冷却至室温,加入二氯甲烷和0.1N HCl溶液,萃取,后静置分层,有机相用饱和食盐水洗涤,无水硫酸钠干燥,抽滤后旋蒸除去溶剂,柱层析分离粗品,得类白色固体25-2,136mg,收率:42.8%。MS(M+1):811.2。
第二步:合成化合物25-3
将25-2(136mg,0.17mmol),氘代甲胺盐酸盐(189mg,2.68mmol)加入到5mL乙腈中,室温搅拌。再向其中加入DBU(613mg,4.03mmol),逐渐溶解澄清。随后将体系置于油浴中回流反应过夜。翌日,冷却至室温,旋蒸除去溶剂后,向体系中加入二氯甲烷以及0.1N HCl溶液,剧烈搅拌,静置分层,有机相分别用纯净水以及饱和食盐水洗涤,无水硫酸钠干燥,旋蒸除去溶剂,Pre-TLC分离纯化(PE/EA=2:1),得白色固体25-3(42mg,收率35.3%)。MS(M-Boc+1):614.2。
第三步:合成化合物25
将25-3(42mg,0.06mmol)加入到2mL二氯甲烷中,室温搅拌(未能溶解澄清)。随后向其中加入0.1mL三氟甲磺酸,体系逐渐呈现透明澄清状,任其在室温搅拌反应过夜。翌日,旋蒸除去溶剂,向体系中加入乙酸乙酯以及饱和NaHCO3溶液,剧烈搅拌,后静置分层,测得水相的pH值约为7-8左右。有机层分别用水以及饱和食盐水洗涤各2次,无水硫酸钠干燥,旋蒸除去溶剂,得白色固体化合物25(24mg,收率:80.0%)。
1HNMR(400Hz,DMSO-d6):δ9.863(1H,s),8.688(1H,d,J=2.4Hz),8.581(1H,d,J=2.8Hz),δ8.316(1H,s),δ8.180(1H,s),7.665-7.594(4H,dd,J1=19.6Hz,J2=8.8Hz),7.476-7.450(1H,t,J=5.2Hz),δ5.001(2H,d,J=4.8Hz),3.221(3H,s),3.199(3H,s).LC-MS(M+H+):514.2。
采用与化合物相对应的原料和类似于化合物25的制备方法,制备得到化合物26-40。
实施例2、合成N-甲基-4-((4-(((3-(N-三氘代甲基甲磺酰胺基)吡嗪-2-基)甲基)氨基)-5-(三氟甲基)嘧啶-2-基)氨基)苯甲酸酰胺(化合物41)
第一步:合成N-三氘代甲基甲磺酰胺(化合物41-1)
氘代甲胺盐酸盐(7.75g,109.99mmol)置于250mL单颈圆底烧瓶中,同时加入二氯甲烷(120mL),室温搅拌。随后将体系移置于冰水浴中降温冷却搅拌,15min后依次加入三乙胺(21.73g,214.75mmol)以及DMAP(128mg,1.05mmol),完毕,体系在冰水浴中继续保温搅拌反应10min。尔后,向体系中加入甲基磺酰氯(12.0g,104.76mmol),完毕,撤去冰浴,让体系在室温搅拌反应过夜。翌日,TLC检测反应结束,对体系进行抽滤操作,滤饼用乙酸乙酯少量多次淋洗,合并滤液,旋蒸除去溶剂,再向体系中加入乙酸乙酯(90mL),剧烈搅拌,10min后,再次对体系进行抽滤操作,滤饼亦用乙酸乙酯少量多次淋洗,合并滤液,真空浓缩得N-三氘代甲基甲磺酰胺(11.16g)无色透明油状液体,不经进一步纯化,直接用于下步反应中。收率:94.9%。LC/MS(ESI+)Calcd for C2H4D3NO2S(M+H+)m/z,113.1;Found:113.3。
第二步:合成N-(3-氰基吡嗪-2-yl)-N-三氘代甲基甲磺酰胺(化合物41-2)
N-三氘代甲基甲磺酰胺(6.0g,53.54mmol),2-氯-3氰基吡嗪(6.23g,44.62mmol)置于500mL单颈圆底烧瓶中,同时加入乙腈(300mL),室温搅拌。随后向体系中加入碳酸铯(24.71g,75.85mmol),完毕,将体系移置于80℃的油浴中继续加热搅拌反应。1.5h后,取样点板,TLC显示原料已经消耗完毕。停止加热,让体系自然冷却至室温。对体系进行抽滤操作,滤饼用乙腈少量多次淋洗,尔后,合并滤液,旋蒸除去溶剂。再向体系中加入乙酸乙酯(150mL)和水(150mL),剧烈搅拌,静置分层,水相用乙酸乙酯反萃(50mL*3),合并有机相,依次用纯净水(30mL x 3),饱和食盐水(30mL)洗涤,无水硫酸钠干燥,真空浓缩得粗品,并通过柱层析分离纯化得N-(3-氰基吡嗪-2-yl)-N-氘代甲基甲磺酰胺(5.29g)浅棕红色油状液体。收率:55.1%。LC/MS(ESI+)Calcd for C7H5D3N4O2S(M+H+)m/z,216.1;Found:233.1(M+H2O)。1H NMR(400MHz,DMSO-d6)δ8.65–8.63(dd,J=6.0,2.4Hz,2H),3.26(s,3H).
第三步:合成N-(3-(氨甲基)吡嗪-2-yl)-N-三氘代甲基甲磺酰胺(化合物41-3)
称取N-(3-氰基吡嗪-2-yl)-N-氘代甲基甲磺酰胺(2.0g,9.30mmol)置于500mL的单颈圆底烧瓶中,并向其中加入甲醇(270mL),室温搅拌溶解澄清。随后,向体系中加入湿钯碳(1g),以及氨水(20mL)。尔后对体系进行抽真空,通氩气的操作反复5次,确保体系中的惰性气体氛围。再对体系进行氢气置换操作,完毕,仍体系在室温搅拌反应。5h后,取样点板,TLC显示原料已经消耗完毕。停止反应,撤去加氢装置。对体系进行抽滤操作,滤饼用甲醇反复淋洗数次,合并滤液,旋蒸除去溶剂,并使用甲醇多次旋带除去体系中残留的水分,得N-(3-(氨甲基)吡嗪-2-yl)-N-氘代甲基甲磺酰胺浅黄棕色透明油状液体,不经进一步纯化,直接用于下步反应中。LC/MS(ESI+)Calcd for C7H9D3N4O2S(M+H+)m/z,220.1;Found:220.1。
第四步:化合物叔丁基(4-(甲基氨甲酰)苯基)氨基甲酸酯的合成
称取4-((叔丁氧羰基)氨基)苯甲酸(3.0g,12.65mmol)置于250mL单颈圆底烧瓶中,并向其中加入50mL DMF,室温搅拌。随后向体系中依次加入EDCI(4.8g,25.29mmol),TEA(4.5g,44.28mmol),甲胺盐酸盐(1.3g,18.98mmol),DMAP(16.0mg,0.13mmol)。完毕,体系在室温搅拌反应过夜。翌日,监测原料消耗完毕,向体系中加入乙酸乙酯(70mL)和水(50mL),剧烈搅拌,静置分层后,水相用乙酸乙酯反萃(20mL*3),合并有机层,分别用水(20mL*3),饱和食盐水(30mL)洗涤,无水硫酸钠干燥,旋蒸除去溶剂得粗品,后经柱层析分离得类白色固体叔丁基(4-(甲基氨甲酰)苯基)氨基甲酸酯2.1g。收率:66.5%。MS(ESI)m/e 251.2(M+H)+。
第五步:化合物4-氨基-N-甲基苯甲酰胺三氟乙酸盐的合成
称取叔丁基(4-(甲基氨基甲酰)苯基)氨基甲酸酯(500.0mg,2.00mmol)置于50mL单颈圆底烧瓶中,并向其中加入10mL二氯甲烷,室温搅拌。尔后,向体系中加入三氟乙酸(1mL),完毕,体系在室温搅拌反应过夜。翌日,TLC显示反应结束。浓缩除去溶剂以及过量的三氟乙酸,并使用二氯甲烷多次旋带除去体系中残留的三氟乙酸直到体系中呈现完全固状为止,得类白色固体4-氨基-N-甲基苯甲酰胺三氟乙酸盐(510.0mg),不经进一步纯化,直接用于下步反应中。
第六步:化合物4-((4-氯-5-(三氟甲基)嘧啶-2-yl)氨基)-N-甲基苯甲酰胺的合成
称取2,4-二氯-5-(三氟甲基)嘧啶(499.0mg,2.30mmol)于50mL单颈圆底烧瓶中,并向体系中加入1,2-二氯乙烷(5mL)和叔丁醇(5mL),室温搅拌溶解澄清。后将体系移置于冰水浴中继续降温冷却搅拌,15min后,向体系中加入溴化锌(1.4g,6.00mmol)。完毕,体系在冰水浴中继续保温搅拌30min。然后向体系中加入前步合成的4-氨基-N-甲基苯甲酰胺三氟乙酸盐以及三乙胺(648.0mg,6.40mmol)。加毕,撤去冰浴,体系在室温搅拌反应过夜。翌日,监测反应结束,旋蒸除去溶剂后,向体系中加入乙酸乙酯(30mL)和水(20mL),剧烈搅拌,静置分层后,水层用乙酸乙酯反萃(10mL*3),合并有机相,依次用水(15mL*3),饱和食盐水(15mL)洗涤,无水硫酸钠干燥,减压浓缩得粗品,后经柱层析分离得类白色固体4-((4-氯-5-(三氟甲基)嘧啶-2-yl)氨基)-N-甲基苯甲酰胺280.0mg。收率:42.3%。MS(ESI)m/e331.0(M+H)+。
第七步:化合物N-甲基-4-((4-(((3-(N-氘代甲基甲磺酰胺基)吡嗪-2-yl)甲基)氨基)-5-(三氟甲基)嘧啶-2-yl)氨基)苯甲酰胺的合成
向装有N-(3-(氨甲基)吡嗪-2-yl)-N-氘代甲基甲磺酰胺(化合物41-3,65.8mg,0.30mmol)的25mL单颈圆底烧瓶中加入5mL 1,2-二氯乙烷,5mL叔丁醇,室温搅拌溶解澄清。随后,向体系中依次加入4-((4-氯-5-(三氟甲基)嘧啶-2-yl)氨基)-N-甲基苯甲酰胺(100.0mg,0.30mmol),二异丙基乙胺(116.3mg,0.90mmol),加毕,将体系移置于80℃的油浴中回流反应。8h后,TLC监测原料消耗完全。停止加热,待体系冷却至室温后,旋蒸除去溶剂得粗品,后经Pre-TLC分离纯化得类白色固体N-甲基-4-((4-(((3-(N-三氘代甲基甲磺酰胺基)吡嗪-2-yl)甲基)氨基)-5-(三氟甲基)嘧啶-2-yl)氨基)苯甲酰胺(化合物41)12mg。收率:7.8%。MS(ESI)m/e 514.2(M+H)+。1H NMR(400MHz,DMSO-d6)δ9.83(s,1H),8.69(s,1H),8.59(s,1H),8.32(s,1H),8.20(d,J=4.0Hz,1H),7.68-7.61(dd,J=14.4,8.4Hz,4H),7.41-7.39(t,J=4.4Hz,1H),5.01(d,J=3.6Hz,2H),3.20(s,3H),2.76(d,J=4.0Hz,3H)。
采用与化合物相对应的原料和类似于化合物41的制备方法,制备得到化合物42和43。
实施例3、合成N-三氘代甲基-4-((4-(((3-(N-三氘代甲基甲磺酰胺基)吡嗪-2-基)甲基)氨基)-5-(三氟甲基)嘧啶-2-基)氨基)苯甲酸酰胺(化合物44)及其盐酸盐
第一步:合成(4-(三氘代甲基氨基甲酰)苯基)氨基甲酸叔丁酯(化合物44-1)
分别称取N-Boc-4-氨基苯甲酸(6.0g,25.29mmol),EDCI(7.27g,37.93mmol)置于250mL单颈圆底烧瓶中,同时加入DMF(50mL),室温搅拌。随后向体系中加入三乙胺(6.40g,63.22mmol),氘代甲胺盐酸盐(1.96g,27.82mmol),完毕,体系在室温搅拌反应过夜。翌日,取样点板,TLC显示反应已经结束。向体系中加入乙酸乙酯(50mL),水(50mL)剧烈搅拌,后静置分层,水相用乙酸乙酯反萃(50mL*3),合并有机相,依次用水(30mL*3),饱和食盐水(50mL)洗涤,无水硫酸钠干燥,真空浓缩得粗品,并通过柱层析分离纯化得(4-(氘代甲基氨基甲酰)苯基)氨基甲酸叔丁酯(4.92g)类白色固体。收率:76.8%。LC/MS(ESI+)Calcd forC13H15D3N2O3(M+H+)m/z,254.2;Found:254.2。
第二步:合成4-氨基-N-三氘代甲基苯甲酰胺三氟乙酸盐(化合物44-2)
称取(4-(氘代甲基氨基甲酰)苯基)氨基甲酸叔丁酯(3.0g,11.84mmol)置于100mL单颈圆底烧瓶中,同时加入二氯甲烷(15mL),室温搅拌。随后向体系中加入三氟乙酸(7mL),完毕,体系在室温搅拌反应。5h后,取样点板,TLC显示反应已经结束。旋蒸除去溶剂以及过量的三氟乙酸,并使用二氯甲烷反复旋带除去残留的三氟乙酸,得类白色固体4-氨基-N-氘代甲基苯甲酰胺三氟乙酸盐。不经进一步纯化,直接用于下步反应中。
第三步:合成4-((4-氯-5-(三氟甲基)嘧啶-2-yl)氨基)-N-三氘代甲基苯甲酰胺(化合物44-3)
称取2,4-二氯-5-三氟甲基嘧啶(2.83g,13.02mmol)置于100mL单颈圆底烧瓶中,同时加入1,2-二氯乙烷(30mL)和叔丁醇(30mL),室温搅拌溶解澄清。随后将体系移置于冰水浴中继续降温冷却搅拌,待体系内温降至约0℃时,向体系中加入溴化锌(8.0g,35.52mmol),完毕,体系在冰水浴中继续保温反应30min。随后,向体系中加入前步反应制得的4-氨基-N-氘代甲基苯甲酰胺三氟乙酸盐以及三乙胺(3.83g,37.89mmol),尔后,撤去冰水浴,让体系在室温搅拌反应过夜。翌日,取样点板,TLC显示原料已经消耗完毕,停止反应。旋蒸除去溶剂,向体系中加入乙酸乙酯(50mL),水(30mL)剧烈搅拌,后静置分层,水相用乙酸乙酯反萃(30mL*3),合并有机相,依次用水(30mL*3),饱和食盐水(30mL)洗涤,无水硫酸钠干燥,真空浓缩得粗品,并通过柱层析分离纯化得4-((4-氯-5-(三氟甲基)嘧啶-2-yl)氨基)-N-氘代甲基苯甲酰胺(3.23g)类白色固体。第二~第三两步反应的收率:81.8%。LC/MS(ESI+)Calcd for C13H7D3ClF3N4O(M+H+)m/z,334.0;Found:334.0。1H NMR(400MHz,DMSO-d6)δ10.89(s,1H),8.87(s,1H),8.31(s,1H),7.84–7.77(m,4H).
第四步:合成N-三氘代甲基-4-((4-(((3-(N-三氘代甲基甲磺酰胺)吡嗪-2-yl)甲基)氨基)-5-(三氟甲基)嘧啶-2-yl)氨基)苯甲酰胺(化合物44)
称取4-((4-氯-5-(三氟甲基)嘧啶-2-yl)氨基)-N-氘代甲基苯甲酰胺(3.1g,9.29mmol),N-(3-氰基吡嗪-2-yl)-N-氘代甲基甲磺酰胺(2.0g,9.29mmol)于250mL单颈圆底烧瓶中,随后向其中加入1,2-二氯乙烷(80mL)和叔丁醇(80mL),室温搅拌溶解澄清。尔后,向体系中加入二异丙基乙胺(3.6g,27.87mmol),完毕,将体系移置于80℃的油浴中回流搅拌反应过夜。翌日,取样点板,TLC显示反应结束。旋蒸除去溶剂,向体系中加入乙酸乙酯(100mL),水(50mL)剧烈搅拌,后静置分层,水相用乙酸乙酯反萃(50mL*3),合并有机相,依次用水(30mL*3),饱和食盐水(50mL)洗涤,无水硫酸钠干燥,真空浓缩得粗品,并通过柱层析分离纯化得目标化合物(2.36g)类白色固体。后将该固体置于250mL单颈圆底烧瓶中,加入乙酸乙酯(75mL),室温搅拌打浆。3h后,对其进行抽滤操作,滤饼用乙酸乙酯(45mL)少量多次淋洗,后置于真空干燥箱中低温干燥,得N-氘代甲基-4-((4-(((3-(N-氘代甲基甲磺酰胺)吡嗪-2-yl)甲基)氨基)-5-(三氟甲基)嘧啶-2-yl)氨基)苯甲酰胺(2.11g)白色固体。收率:44.0%。LC/MS(ESI+)Calcd for C20H15D6F3N8O3S(M+H+)m/z,517.2;Found:517.2。1HNMR(400MHz,DMSO)δ9.83(s,1H),8.69(d,J=2.8Hz,1H),8.58(d,J=2.4Hz,1H),8.31(s,1H),8.17(s,1H),7.67–7.61(dd,J=15.4,8.6Hz,4H),7.41(t,J=5.0Hz,1H),5.00(d,J=4.8Hz,2H),3.20(s,3H).
第五步:合成N-氘代甲基-4-((4-(((3-(N-氘代甲基甲磺酰胺)吡嗪-2-基)甲基)氨基)-5-(三氟甲基)嘧啶-2-基)氨基)苯甲酰胺盐酸盐
称取化合物44(500mg,0.97mmol)置于100mL单颈圆底烧瓶中,并向其中加入甲醇(25mL),室温搅拌均匀。随后向体系中缓慢地滴加氯化氢的乙醇溶液(2.25mL,2.0M),完毕,体系继续在室温搅拌反应。1.5h后,对体系进行抽滤操作,滤饼用甲醇(15mL)少量多次淋洗,后置于真空干燥箱中低温干燥,得N-氘代甲基-4-((4-(((3-(N-氘代甲基甲磺酰胺)吡嗪-2-yl)甲基)氨基)-5-(三氟甲基)嘧啶-2-yl)氨基)苯甲酰盐酸盐(517mg),为类白色固体。收率:96.6%。LC/MS(ESI+)Calcd for C20H16D6ClF3N8O3S(M+H+)m/z,517.2;Found:517.2。1H NMR(400MHz,DMSO)δ10.02(s,1H),8.68(d,J=2.8Hz,1H),8.58(d,J=2.4Hz,1H),8.35(s,1H),8.21(s,1H),7.67–7.57(m,5H),5.26(br,6H)5.00(d,J=4.8Hz,2H),3.19(s,3H).
实施例4、合成N-氘代甲基-4-((4-(((3-(N-氘代甲基甲磺酰胺基)吡嗪-2-基)氘代甲基)氨基)-5-(三氟甲基)嘧啶-2-基)氨基)苯甲酰胺(化合物45)
第一步:合成化合物N-(3-(氨基二氘代甲基)吡嗪-2-基)-N-氘代甲基甲磺酰胺(45-1)
称取化合物41-2(100.0mg,0.46mmol)置于25mL单颈圆底烧瓶中,并加入5mL氘代甲醇,室温搅拌溶解澄清。随后向体系中依次加入湿钯碳(使用重水处理)20.0mg,三乙胺(188.2mg,1.86mmol),对体系进行氘气置换操作,反复十次。完毕,体系在室温搅拌反应。72h后,监测反应结束。对体系进行抽滤操作,滤饼用氘代甲醇(10mL)少量多次淋洗,合并滤液,旋蒸除去溶剂,得浅黄褐色油状液体N-(3-(氨基氘代甲基)吡嗪-2-基)-N-氘代甲基甲磺酰胺,不经进一步纯化,直接用于下步反应中。MS(ESI)m/e 222.2(M+H)+。
第二步:合成化合物N-氘代甲基-4-((4-(((3-(N-氘代甲基甲磺酰胺基)吡嗪-2-基)氘代甲基)氨基)-5-(三氟甲基)嘧啶-2-基)氨基)苯甲酰胺(45)
向装有N-(3-(氨基氘代甲基)吡嗪-2-基)-N-氘代甲基甲磺酰胺(22.1mg,0.10mmol)的25mL单颈圆底烧瓶中加入2mL 1,2-二氯乙烷,2mL叔丁醇,室温搅拌溶解澄清。随后,向体系中依次加入化合物44-3(33.4mg,0.10mmol),二异丙基乙胺(30.6mg,0.30mmol),加毕,将体系移置于80℃的油浴中回流反应。8h后,TLC监测原料消耗完全。停止加热,待体系冷却至室温后,旋蒸除去溶剂得粗品,后经Prep-TLC分离纯化得类白色固体N-氘代甲基-4-((4-(((3-(N-氘代甲基甲磺酰胺基)吡嗪-2-基)甲基)氨基)-5-(三氟甲基)嘧啶-2-基)氨基)苯甲酰胺8.1mg。收率:15.6%。MS(ESI)m/e 519.2(M+H)+。1H NMR(400MHz,DMSO-d6)δ9.83(s,1H),8.69(d,J=2.0Hz,1H),8.58(d,J=2.4Hz,1H),8.31(s,1H),8.17(s,1H),7.67-7.61(dd,J=15.2,8.8Hz,4H),7.39(s,1H),3.20(s,3H)。
实施例5、合成4-((4-(((3-(N-三氘代甲基甲磺酰胺)吡嗪-2-基)甲基)氨基)-5-(三氟甲基)嘧啶-2-基)氨基)苯甲酰胺(化合物52)
第一步:合成化合物4-((4-氯-5-(三氟甲基)嘧啶-2-基)氨基)苯甲酰胺(52-2)
称取2,4-二氯-5-(三氟甲基)嘧啶(434mg,2.00mmol)于50mL单颈圆底烧瓶中,并向体系中加入1,2-二氯乙烷(5mL)和叔丁醇(5mL),室温搅拌溶解澄清。后将体系移置于冰水浴中继续降温冷却搅拌,15min后,向体系中加入溴化锌(1.2g,5.22mmol)。完毕,体系在冰水浴中继续保温搅拌30min。然后向体系中加入前步合成的4-氨基苯甲酰胺(237mg,1.74mmol)以及三乙胺(564mg,5.57mmol)。加毕,撤去冰浴,体系在室温搅拌反应过夜。翌日,监测反应结束,旋蒸除去溶剂后,向体系中加入乙酸乙酯(30mL)和水(20mL),剧烈搅拌,静置分层后,水层用乙酸乙酯反萃(10mL*3),合并有机相,依次用水(15mL*3),饱和食盐水(15mL)洗涤,无水硫酸钠干燥,减压浓缩得粗品,后经柱层析分离得类白色固体4-((4-氯-5-(三氟甲基)嘧啶-2-基)氨基)苯甲酰胺294mg。收率:53.4%。MS(ESI)m/e 317.0(M+H)+。第二步:合成化合物4-((4-(((3-(N-三氘代甲基甲磺酰胺)吡嗪-2-基)甲基)氨基)-5-(三氟甲基)嘧啶-2-基)氨基)苯甲酰胺(52)
向装有前述制得的化合物52-2的25mL单颈圆底烧瓶中加入5mL 1,2-二氯乙烷,5mL叔丁醇,室温搅拌溶解澄清。随后,向体系中依次加入化合物44-3(63.0mg,0.20mmol),二异丙基乙胺(78mg,0.60mmol),加毕,将体系移置于80℃的油浴中回流反应。翌日,TLC监测原料消耗完全。停止加热,待体系冷却至室温后,旋蒸除去溶剂得粗品,后经Prep-TLC分离纯化得类白色固体4-((4-(((3-(N-氘代甲基甲磺酰胺)吡嗪-2-基)甲基)氨基)-5-(三氟甲基)嘧啶-2-基)氨基)苯甲酰胺22mg。收率:22.0%。MS(ESI)m/e 500.1(M+H)+。1H NMR(400MHz,DMSO-d6)δ9.83(s,1H),8.69(s,2H),8.60(s,1H),8.31(s,1H),8.20(d,J=4.0Hz,1H),7.68-7.60(dd,J=15.4,8.4Hz,4H),7.41-7.39(t,J=4.4Hz,1H),5.03(d,J=3.6Hz,2H),3.20(s,3H)。
用已知化合物4-氨基-3,5-二氘代苯甲酸,4-氨基-2,6-二氘代苯甲酸(Journalof Labelled Compounds and Radiopharmaceuticals,53(11-12),668-673;2010)为原料,参照上述实施例的方法制备得到化合物48-50,53-55。用已知化合物4-氨基-2,3,5,6-四氘代苯甲酸(Journal of Natural Products,79(6),1532-1537;2016)为原料,参照上述实施例的方法制备得到化合物59-61。
以下通过试验例证明本发明的有益效果。
试验例1、本发明氘代化合物对FAK的抑制活性
(1)试验方法
参照文献方法(Cancer Res.2008,68,1935)进行FAK酶抑制活性实验。具体如下:待测化合物稀释至1000nM,然后用DMSO按1:3逐级稀释取0.1L溶液放入384孔板中,每个浓度设置2个复孔。加入5L2倍FAK酶溶液,在1000rpm离心1分钟,在25℃孵化15分钟。加入5L2倍底物溶液在25℃孵化60分钟。再加入5L Sa-XL665溶液和5μL TK抗体-Eu3+,在1000 rpm离心1分钟,在25℃孵化60分钟,最后用Envision 2104读板机读取荧光信号,并计算出各化合物对FAK酶的半数抑制浓度IC50。以已知的FAK抑制剂defactinib为对照。
(2)试验结果
各化合物对FAK抑制活性如表1所示。可以看出,本发明制得的化合物能够有效抑制FAK酶的活性,并且,与未氘代的化合物defactinib相比,本发明的氘代化合物41、45对FAK酶的抑制活性更高。
表1、本发明化合物对FAK酶的抑制活性
化合物 | defactinib | 41 | 44 | 45 | 46 |
IC50(nM) | 0.24 | 0.20 | 0.47 | 0.15 | 0.37 |
试验例2、本发明氘代化合物的大鼠药代动力学测试
(1)试验方法
精密称取适量待测药物(10mg),先加入N,N-二甲基乙酰胺(DMA)0.25ml使之溶解,然后缓慢加入0.5%羧甲基纤维素钠(CMC-Na)至5ml,超声、涡漩混匀。取上述配制的终溶液0.2ml,于-20℃保存,用于浓度测定。
健康成年雄性SD大鼠3只(180-250g,购自成都达硕实验动物有限公司),禁食过夜(自由饮水)后,灌胃给药,给药体积5ml/kg;于给药前及给药后0.5,1,2,4,6,8,12,24h由眼眶后静脉丛采血0.1ml,4℃离心5min分离血浆,于-20℃保存待测。然后采用LC/MS/MS法测定血浆中的待测化合物浓度。以已知的FAK抑制剂defactinib为对照。
(2)试验结果
表2、本发明化合物的药代动力学参数
如表2所示,与defactinib相比,本发明制得的氘代化合物25、44显示了更优的药代动力学,本发明的化合物具有更高的最高血药浓度Cmax,更高的暴露量AUC,和更长的半衰期。所以,本发明制得的氘代化合物在作为FAK抑制剂或治疗癌症的药物中将具有更优的应用前景。
试验例3、本发明氘代化合物联合PD-1抑制剂在肿瘤动物模型上的药效实验
1.MC38肿瘤模型:
(1)试验方法
细胞培养:MC-38细胞培养在含10%胎牛血清(FBS)的DMEM培养液中。收集对数生长期的MC-38细胞,HBSS重悬至适合浓度用于C57BL/6小鼠皮下肿瘤接种。
实验动物:C57BL/6小鼠,雌性,6-8周龄,体重约18-20g,96只,购自于北京维通利华实验动物技术有限公司。
肿瘤细胞接种:收集对数生长期肿瘤细胞,用HBSS将细胞浓度调整为5×106/mL,用1mL注射器接种0.1mL于每只小鼠右侧靠近背部皮下,即5×105/只。之后观察和测量肿瘤体积,待小鼠平均瘤体积长至50-100mm3时,根据肿瘤体积对荷瘤鼠进行随机分组并给药,详细信息如下表3,分组给药当天定义为第0天。
计算肿瘤体积:于第18天处死小鼠,取出肿瘤,测量肿瘤体积,并计算各组抑瘤率。
表3、MC38肿瘤模型分组,给药信息及抑瘤率
注:N:使用动物数量;i.p.:腹腔注射;p.o.:灌胃给药;BID:每天两次;QD:每天一次;BIW:每周两次。
(2)试验结果
动物给药18天后的药效如图1所示,计算出的抑瘤率见表3。可以看出本发明化合物44单用的药效比mPD-1抗体单用的药效更佳,说明本发明化合物单独给药对MC38肿瘤模型小鼠有治疗效果。
此外,与化合物44单用(第4组)或mPD-1抗体单用(第2组)相比,化合物44联合mPD-1抗体给药(第5组)取得了显著提高的肿瘤抑制效果,发挥了协同增效的作用。
另外,与Defactinib(50mg/kg,每天2次给药)联合mPD-1抗体给药(第3组)相比,本发明化合物44(50mg/kg,每天一次给药)联合mPD-1抗体给药(第5组)后的肿瘤抑制效果更佳,取得了更优异的肿瘤抑制效果。也就是说,在与PD-1抑制剂联用时,采用Defactinib一半剂量的本发明化合物,却能取得更佳的肿瘤抑制效果,说明本发明化合物与PD-1抑制剂联合用药对MC38肿瘤模型的抗肿瘤效果显著优于Defactinib与PD-1抑制剂联合用药。
2.PAN02肿瘤模型
(1)试验方法
取处于对数生长期的PAN-02细胞,用PBS洗两次,然后重悬于预冷PBS中用于接种。实验动物为C57BL/6小鼠,雌性,购自北京维通利华实验动物技术有限公司。C57BL/6小鼠实验室环境适应3天,于右肋部皮下接种PAN-02细胞,接种细胞量为1×106/只,待肿瘤生长至100mm3左右时进行筛选、随机分组,每组8只,按下表4分组和给药方案给药。分组给药当天定义为第1天,给药周期为33天。
表4、PAN-02肿瘤模型分组,给药信息及抑瘤率
注:N:使用动物数量;i.p.:腹腔注射;i.g.:灌胃给药;BID:每天两次;BIW:每周两次。
(2)试验结果
动物给药33天后的药效如图2所示,计算出的抑瘤率见表4。可以看出,与化合物44单用(第4组)或mPD-1抗体单用(第2组)相比,化合物44联合mPD-1抗体给药(第5组)取得了显著提高的肿瘤抑制效果。
同时,与Defactinib(50mg/kg,每天2次给药)联合mPD-1抗体给药(第3组)后的肿瘤抑制效果相比,本发明化合物44(25mg/kg,每天两次给药)联合mPD-1抗体给药(第5组)后的肿瘤抑制效果显著提高。也就是说,在与PD-1抑制剂联用时,采用比Defactinib更低剂量的本发明化合物,反而能取得更加优异的肿瘤抑制效果,说明本发明化合物与PD-1抑制剂联合用药对PAN-02肿瘤模型的抗肿瘤效果显著优于Defactinib与PD-1抑制剂联合用药。
综上,本发明提供了一种氘代化合物,与氘代前的化合物相比,其显示了更优的药代动力学,更高的最高血药浓度,更高的暴露量和更长的半衰期,具有更加优异的代谢性能。而且,本发明的氘代化合物能够有效抑制FAK活性,在制备FAK抑制剂和/或治疗癌症的药物中具有非常好的应用前景。同时,本发明的氘代化合物与抗癌药物(比如PD-1抑制剂)联合使用能够发挥协同增效的作用,显著提高肿瘤抑制效果,为临床治疗癌症提供了更好的选择。
Claims (2)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811614990 | 2018-12-27 | ||
CN2018116149902 | 2018-12-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111377871A CN111377871A (zh) | 2020-07-07 |
CN111377871B true CN111377871B (zh) | 2021-03-19 |
Family
ID=71128495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911350837.8A Active CN111377871B (zh) | 2018-12-27 | 2019-12-24 | 一种fak抑制剂及其联合用药物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220125788A1 (zh) |
EP (1) | EP3904351A4 (zh) |
JP (1) | JP2022515273A (zh) |
KR (1) | KR20210110846A (zh) |
CN (1) | CN111377871B (zh) |
AU (1) | AU2019414550B2 (zh) |
BR (1) | BR112021012682A2 (zh) |
CA (1) | CA3125058C (zh) |
WO (1) | WO2020135442A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112592318B (zh) * | 2020-12-12 | 2022-05-03 | 贵州医科大学 | 2-(4-甲氨酰基)苯胺基-4-氨基嘧啶衍生物及应用 |
AU2022207035A1 (en) * | 2021-01-18 | 2023-09-07 | Hinova Pharmaceuticals Inc. | Synthesis method for aminopyrimidine fak inhibitor compound |
CN115192717B (zh) * | 2021-04-08 | 2023-12-12 | 海创药业股份有限公司 | 一种治疗癌症的药物组合物及其用途 |
CN113372334B (zh) * | 2021-05-25 | 2022-05-03 | 贵州医科大学 | 2-(4-甲氨酰基)苯胺基-4-氨基-5-三氟甲基嘧啶衍生物及其应用 |
AU2022282251A1 (en) * | 2021-05-25 | 2024-01-18 | Hinova Pharmaceuticals Inc. | Pharmaceutical composition for treatment of cancer and use thereof |
CN115403583B (zh) * | 2021-05-28 | 2023-06-30 | 四川大学 | 一种靶向降解fak蛋白的化合物及其用途 |
WO2023138630A1 (zh) * | 2022-01-21 | 2023-07-27 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
WO2024037498A1 (zh) * | 2022-08-15 | 2024-02-22 | 海创药业股份有限公司 | 一种治疗卵巢癌的联合用药物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2593486T3 (es) * | 2007-04-18 | 2016-12-09 | Pfizer Products Inc. | Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo |
US20110053968A1 (en) * | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
CN102459180B (zh) * | 2009-06-09 | 2014-05-14 | 江苏迈度药物研发有限公司 | 作为激酶抑制剂的脲衍生物 |
MX2018000288A (es) * | 2015-06-29 | 2018-11-09 | Verastem Inc | Composiciones terapeuticas, combinaciones y metodos de uso. |
CN106146406A (zh) * | 2016-02-23 | 2016-11-23 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的二氨基嘧啶类化合物及包含该化合物的组合物及其用途 |
WO2017201043A1 (en) * | 2016-05-16 | 2017-11-23 | Concert Pharmaceuticals, Inc. | Combination therapy for treating cancer |
JP2021528370A (ja) * | 2018-05-07 | 2021-10-21 | ヒノバ ファーマシューティカルズ インコーポレイテッド | 重水素化デファクチニブ化合物及びその使用 |
-
2019
- 2019-12-24 AU AU2019414550A patent/AU2019414550B2/en active Active
- 2019-12-24 CA CA3125058A patent/CA3125058C/en active Active
- 2019-12-24 KR KR1020217023858A patent/KR20210110846A/ko not_active Application Discontinuation
- 2019-12-24 CN CN201911350837.8A patent/CN111377871B/zh active Active
- 2019-12-24 JP JP2021537154A patent/JP2022515273A/ja active Pending
- 2019-12-24 WO PCT/CN2019/128030 patent/WO2020135442A1/zh unknown
- 2019-12-24 EP EP19902488.6A patent/EP3904351A4/en active Pending
- 2019-12-24 BR BR112021012682-1A patent/BR112021012682A2/pt unknown
- 2019-12-24 US US17/418,678 patent/US20220125788A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3904351A4 (en) | 2022-09-14 |
EP3904351A1 (en) | 2021-11-03 |
AU2019414550A1 (en) | 2021-07-22 |
US20220125788A1 (en) | 2022-04-28 |
CN111377871A (zh) | 2020-07-07 |
CA3125058C (en) | 2023-10-03 |
CA3125058A1 (en) | 2020-07-02 |
KR20210110846A (ko) | 2021-09-09 |
JP2022515273A (ja) | 2022-02-17 |
WO2020135442A1 (zh) | 2020-07-02 |
BR112021012682A2 (pt) | 2021-09-08 |
AU2019414550B2 (en) | 2022-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111377871B (zh) | 一种fak抑制剂及其联合用药物 | |
EP2990405B1 (en) | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | |
JP6139782B2 (ja) | 置換ピラゾロピリミジン化合物、及びその薬学的に許容される塩、並びにこれらの溶媒和物、立体異性体、及び互変異性体、並びにこれらを含む医薬組成物 | |
WO2016015453A1 (zh) | 吡啶胺基嘧啶衍生物、其制备方法及应用 | |
JP6404332B2 (ja) | 新規な、NIK阻害剤としての3−(1H−ピラゾール−4−イル)−1H−ピロロ[2,3−c]ピリジン誘導体 | |
JP2020528907A5 (zh) | ||
JP6616411B2 (ja) | 新規な、nik阻害剤としてのピラゾール誘導体 | |
ES2818652T3 (es) | Sal de derivado de piridinilaminopirimidina, método de preparación de la misma y aplicación de la misma | |
TWI321566B (en) | Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof | |
WO2021249563A1 (zh) | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 | |
WO2022083657A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
JP2020505457A (ja) | 2−アリールスルホンアミド−N−アリールアセトアミド誘導体化Stat3 | |
WO2020038433A1 (zh) | 一种egfr激酶抑制剂及其制备方法和应用 | |
CN105985342A (zh) | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 | |
CN106232602B (zh) | 氘代喹唑啉酮化合物以及包含该化合物的药物组合物 | |
WO2022095910A1 (zh) | 用作激酶抑制剂的化合物及其应用 | |
CN111362924A (zh) | 氘代的嘧啶衍生物及其用途 | |
BR112021013099A2 (pt) | Composto de benzotiofeno substituído contendo flúor, e composição farmacêutica e aplicação dos mesmos | |
WO2022171018A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
CN112209933B (zh) | 含有4-氮杂螺庚烷的btk抑制剂 | |
CN113582994B (zh) | 具有trk激酶抑制活性的化合物、制备方法、组合物及其用途 | |
CN117800989A (zh) | 一类含环外双键、多取代甲基醚结构的化合物及其应用 | |
TW202406539A (zh) | 藥物組合及其用途 | |
CN113354630A (zh) | 一种5,6-二氢苯并[h]喹唑啉类化合物及其应用 | |
TW201229047A (en) | Pyridone amide derivatives, preparation process and pharmaceutical use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: No.2 and No.3, floor 4, building 1, Rongyao building, No.5 Keyuan South Road, Chengdu, Sichuan 610000 Applicant after: Haichuang Pharmaceutical Co., Ltd Address before: No.1, floor 4, building a, Rongyao building, No.5 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610000 Applicant before: Chengdu Haichuang Pharmaceutical Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |